A development-stage pharmaceutical company focused on the acquisition, development and commercialization of prescription drugs for the treatment of drug addiction.


Updates from The Motley Fool

Latest updates on Catalyst Pharmaceuticals from Fool.com.
This Week in Biotech: Part 2

A look at the biggest stories this week in biotech and what they mean for investors.



Stock Performance

View Interactive CPRX Charts
Sponsored by

Key Data Points

Primary metrics and data points about Catalyst Pharmaceuticals.
Current Price: $1.10
Prev Close: $1.10
Open: $1.10
Bid: $1.06
Ask: $1.15
Day's Range: $1.08 - $1.12
52wk Range: $0.51 - $1.58
Volume: 247,694
Avg Vol 358,249
Market Cap: $91M
P/E (ttm): -4.58
EPS (ttm): ($0.24)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Catalyst Pharmaceuticals.
CAPS Rating 2 out of 5
 
59 Outperform
10 Underperform
CAPS All Stars
 
5 Outperform
1 Underperform

How do you think Catalyst Pharmaceuticals will perform against the market?



You pick for Catalyst Pharmaceuticals is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Patrick J. McEnany, CEO

0% Approve

Based on 0 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Catalyst Pharmaceuticals.

A development-stage pharmaceutical company focused on the acquisition, development and commercialization of prescription drugs for the treatment of drug addiction.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers